Clinical trial
Direct Implantation of Rapamycin-Eluting Stents With Bio-Erodible Drug Carrier Technology Utilizing the Second Generation Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS)
NCT01788150 is registered in ClinicalTrials.gov with Svelte Medical Systems, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Direct Implantation of Rapamycin-Eluting Stents With Bio-Erodible Drug Carrier Technology Utilizing the Second Generation Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS)
- Lead sponsor
- Svelte Medical Systems, Inc.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- January 31, 2013
- Completion date
- May 31, 2019
- Enrollment
- 159 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.